8-K
0000893949false00008939492022-05-122022-05-12

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 12, 2022

 

 

Mednax, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Florida

001-12111

26-3667538

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

1301 Concord Terrace

 

Sunrise, Florida

 

33323

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 954 384-0175

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $.01 per share

 

MD

 

The New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 


Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 12, 2022, Mednax, Inc., a Florida corporation (the “Company”), appointed James D. Swift, M.D. as an Executive Vice President and the Company’s Chief Operating Officer. Dr. Swift joined the Company in September 2009 and most recently served as the Company’s Executive Vice President and Chief Development Officer. Dr. Swift received his medical degree from the University of Health Sciences/The Chicago Medical School and is board certified in pediatrics.
 

 

There are no arrangements or understandings between Dr. Swift and any other person pursuant to which he was appointed as Chief Operating Officer of the Company and no family relationships between Dr. Swift and any director or executive officer of the Company. Other than as described in this Current Report on Form 8-K, since the beginning of the Company’s last fiscal year, the Company has not engaged in any transactions, and there are no proposed transactions, or series of similar transactions, in which the Company was or is to be a participant and in which Dr. Swift had a direct or indirect material interest in which the amount involved exceeds or exceeded $120,000.

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

On May 12, 2022, the Company held its 2022 Annual Shareholders’ Meeting (the “Annual Meeting”). Of the 87,185,960 shares of common stock outstanding and entitled to vote, 81,415,617 shares were represented, constituting a quorum. The final results for each of the matters submitted to a vote of the Company’s shareholders at the Annual Meeting are as follows:

 

Proposal 1: All of the nominees for the Company’s Board of Directors were elected to serve until the Company’s 2023 Annual Shareholders’ Meeting or until their respective successors are elected and qualified, by the votes set forth in the table below:

 

Name

 

For

 

 

Against

 

 

Abstained

 

 

Broker
Non-Vote

 

Laura A. Linynsky

 

 

79,610,598

 

 

 

269,397

 

 

 

44,907

 

 

 

1,490,715

 

Thomas A. McEachin

 

 

77,319,861

 

 

 

2,559,102

 

 

 

45,939

 

 

 

1,490,715

 

Roger J. Medel, M.D.

 

 

79,208,485

 

 

 

691,198

 

 

 

25,219

 

 

 

1,490,715

 

Mark S. Ordan

 

 

76,784,354

 

 

 

3,094,598

 

 

 

45,950

 

 

 

1,490,715

 

Michael A. Rucker

 

 

79,340,219

 

 

 

538,830

 

 

 

45,853

 

 

 

1,490,715

 

Guy P. Sansone

 

 

79,293,875

 

 

 

585,173

 

 

 

45,854

 

 

 

1,490,715

 

John M. Starcher, Jr.

 

 

70,763,543

 

 

 

9,114,284

 

 

 

47,075

 

 

 

1,490,715

 

Shirley A. Weis

 

 

70,040,888

 

 

 

9,358,513

 

 

 

525,501

 

 

 

1,490,715

 

 

 

Proposal 2: The appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the 2022 fiscal year was ratified by the Company’s shareholders, by the votes set forth in the table below:

 

For

 

 

Against

 

 

Abstained

 

 

Broker
Non-Vote

 

 

78,286,794

 

 

 

3,104,901

 

 

 

23,922

 

 

 

0

 

 

 

Proposal 3: The Company’s shareholders advised against the compensation of the Company’s named executive officers for the 2021 fiscal year, by the votes set forth in the table below:

 

For

 

 

Against

 

 

Abstained

 

 

Broker
Non-Vote

 

 

34,566,404

 

 

 

45,167,188

 

 

 

191,310

 

 

 

1,490,715

 

 

 

The Company regularly makes efforts to engage with its shareholders and intends to continue to conduct additional outreach to its shareholders in the coming months regarding the outcome of the shareholder advisory vote on compensation of the Company’s named executive officers for the 2021 fiscal year.

 

Proposal 4: The Company’s shareholders approved the Second Amended and Restated Articles of Incorporation by the votes set forth in the table below:

 


For

 

 

Against

 

 

Abstained

 

 

Broker
Non-Vote

 

 

79,850,606

 

 

 

26,115

 

 

 

48,181

 

 

 

1,490,715

 

 

 

 

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

Mednax, Inc.

 

 

 

 

Date:

May 17, 2022

By:

/s/ C. Marc Richards

 

 

 

C. Marc Richards

Chief Financial Officer